Prescribed by clinicians, applied by patients.

VERIS™, powered by collagen and Manuka honey, is the first advanced wound care product to deliver on performance, ease, and affordability for the millions recovering from Mohs surgery, biopsies, and chronic ulcers.

Recovery starts with VERIS™ *

  • 2x faster wound closure

  • Decreased pain

  • 99.99% bacteria reduction in 24 hrs

  • Inflammation reduction

  • Growth factor release

*Based on clinical and in vitro data; claims have not been cleared by the FDA. Faster wound closure reported in slower healing and chronic wounds compared to standard of care. View supporting information here.

Effortless for Clinicians

  • Similar to a pharmaceutical product, VERIS™ is easily prescribed at the patient visit.

  • Ordering takes seconds and SweetBio® supports EMR automation.

  • No inventory to carry, VERIS™ + supplies are shipped directly to the patient.

Empowering for Patients

  • Just like a mail-order prescription, VERIS™ arrives at the patient’s home with 30 days of wound supplies.

  • Provided in a convenient non-sticky sheet, VERIS™ is as simple as adding a layer under a bandage. Simply peel open, hydrate, place and cover.

  • For easy maintenance, VERIS™ dissolves daily as the wound progresses with no painful removal process.

VERIS™ is cost-effective

  • Similar to a pharmaceutical product, VERIS™ is prescribed at the patient’s visit at no cost or billing effort from the clinic. 

  • • VERIS™ is covered by Medicare and commercial plans.

    • VERIS™ is billed by insurances under HCPCS A6021 as a low-cost wound supply.

    • Most patients receive VERIS™ at no charge.

  • Unlike skin substitute wound care products, VERIS™ is offered at a fraction of the cost. 

PATENTED MX® TECHNOLOGY

Unique Chemical Fingerprint, Broken Down to be Rebuilt.

  • SweetBio®’s MX® technology embodies a paradigm shift in biomaterials by liberating three natural ingredients from their limitations.

    We meticulously deconstructed natural elements to reimagine and rebuild a new biomaterial with a unique chemical fingerprint that transcends the mere sum of its parts.

    The deliberate selection of ingredients by biomedical engineers has led to the creation of revolutionary wound healing products tailored to address the specific demands of the healing process.

  • A natural extracellular matrix protein, an essential part of organic tissue.

  • 100% UMF-certified New Zealand Manuka honey, known for antibacterial properties and aiding in wound healing.

  • A naturally occurring mineral known to add structural reinforcement to biomaterials.

VERIS™ in Action

OVERVIEW

Procedure: 2 lower leg biopsies performed by a board-certified Mohs surgeon.

Patient: 65-year-old female, Medicare-insured

Concern: Patient returned 2 weeks post-biopsies with no wound closure.

Clinician Process: VERIS™ was prescribed by clinician. SweetBio® logistics partner fulfilled order and billed patient insurance at no charge to patient.

Patient Process: Patient changed their own dressings at home.

Results: Wounds closed in 3-6 weeks, when expected time to closure was 12 weeks.

Before + After

*Pictures taken and shared with patient consent.

“The product is not just hastening the closure of wounds; it empowers patients to take control of their recovery at home. Seamless for me and simple for my patients.”

GWEN BEARD, MD
MOHS SURGEON / MEMPHIS DERMATOLOGY

Backed by Evidence

  • Clinical Publication: 37 Patient Mohs Dermatologic Surgery RCT

    Published in Dermatologic Surgery, this randomized controlled trial (RCT) conducted by the Dermatology Department at Vanderbilt University Medical Center compared SweetBio®’s technology and secondary intention healing (SIH) to support wound closure post-Mohs. Results demonstrated improved wound healing with SweetBio®’s technology showing significant reduction in pain scores and favorable skin thickness.

    Download

  • Clinical Publication: 12 Patient Lower Extremity Chronic Wound Case Series

    Published in The International Journal of Lower Extremity Wounds, this clinical evaluation involved 5 physicians across 4 states using SweetBio®’s technology to treat non-healing chronic ulcers. Patients achieved 100% closure within 8 weeks, with a mean closure time of 4.1 weeks.

    Download

  • Clinical Publication: 8 Patient Mohs Dermatologic Surgery Case Series

    Published in Dermatologic Surgery, this clinical evaluation conducted by the Dermatology Department at Vanderbilt University Medical Center used SweetBio®’s technology to support wound closure post Mohs (skin cancer removal) surgery. Results demonstrated complete re-epithelialization was achieved within an average of 6 weeks.

    Download

  • Clinical Publication: 43 Patient Chronic Wound Healing in an Urban Hospital Wound Clinic

    Published in Wounds, this retrospective IRB-approved clinical evaluation assessed chronic wound closure rates using standard of care (SOC) or treatment with SweetBio®’s technology in an urban hospital wound clinic. In both groups, most wounds did not close for several reasons, mainly patient compliance. For wounds that did close, the average time to closure was two times faster for SweetBio®’s technology compared to SOC (7.4 weeks and 14.8 weeks, respectively; p < .05).

    Download

  • In Vitro Publication: Bacteria Reduction

    Published in Biomedical & Translational Science, this data demonstrates SweetBio®’s technology ability to significantly reduce both Staphylococcus Aureus and Pseudomonas Aeruginosa by 99.99% compared to a non-treated surface after 24 hours, in vitro.

    Download

  • In Vitro Publication: Controlling Inflammation and Growth Factors

    Published in the International Journal of Biomaterials, this data demonstrates SweetBio®’s technology ability to significantly decrease (to negligible levels) the expression of MMP-9 from macrophages and trigger the release of pro-regenerative growth factors from fibroblasts such as FGFb and VEGF, in vitro.

    Download

  • In Vitro Publication: Direct Comparison of Collagen Dressing vs. Manuka Honey Dressing vs. SweetBio®’s Technology

    Published in the International Journal of Molecular Sciences, this data highlights the superior comprehensive approach that SweetBio®’s technology has over collagen dressings and Manuka honey dressings, specifically comparing MMP-9/TIMP-1 ratios and pro-regenerative growth factor secretion, in vitro.

    Download

VERIS™ is Simple for Patients

Hydrate

Apply

Cover

"The easy-to-use packaging of VERIS™ has made self-application convenient, even while traveling, allowing me to maintain my wound care routine without hassle."

VERIS™ PATIENT

Clinician Ordering Process

  • Document the wound attributes in chart notes:

    • Size (LxWxD)

    • Origin (surgically created, stalled, or debrided)

    • Thickness (full)

    • Drainage (light or moderate)

  • Add 30-day supply of VERIS™ to chart notes.

    Include saline and seondary dressing based on wound location, wound size, and level of exudate.

  • Fax face sheet + chart notes to SweetBio®’s 3rd party logistics (DME) partner.

    • Contact info@sweetbio.com for your region’s DME partner

  • Evaluate wound on normal follow-up schedule.

    • Prescribe additional supplies as needed

  • Contact info@sweetbio.com to learn more on how we can automate ordering with your EMR.

    Get onboarded in 10 minutes to place orders in seconds.

Frequently Asked Questions

  • Whether surgically created or stalled, VERIS™ can be used on most wounds. VERIS™ is FDA cleared for the management of a variety of wounds, including surgical sites (Mohs, biopsies, etc.) and ulcers (diabetic, venous stasis, pressure).

    Indications:

    Full and Partial-Thickness Wounds

    Pressure Ulcers (Stages I -IV)

    Venous Stasis Ulcers

    Diabetic Ulcers

    Surface Wounds

    Traumatic Wounds

    Surgical Wounds

    Abrasions

    Donor Sites

  • No, VERIS™ works well even when set in the wound bed and does not overlap the edges of the wound.

  • SweetBio® will provide an easy-to-follow script for you to support your patients expectations.

    Email info@sweetbio.com for patient educational materials.

Contact